NCT03322267View on ClinicalTrials.gov

Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 27, 2018

Primary Completion Date

January 31, 2024

Study Completion Date

December 30, 2025

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Pembrolizumab

Cisplatin (30 mg/m2, QW, 2 cycles) and radiotherapy (18-26 Gy/10-13 fractions) as adjuvant chemoradiotherapy, followed by pembrolizumab (200mg, Q3W, 18 cycles)

Trial Locations (1)

10002

National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

National Taiwan University Hospital

OTHER

NCT03322267 - Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence | Biotech Hunter | Biotech Hunter